282 related articles for article (PubMed ID: 33242189)
1.
Sinnes JP; Bauder-Wüst U; Schäfer M; Moon ES; Kopka K; Rösch F
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):28. PubMed ID: 33242189
[TBL] [Abstract][Full Text] [Related]
2. AAZTA
Sinnes JP; Nagel J; Rösch F
EJNMMI Radiopharm Chem; 2019 Aug; 4(1):18. PubMed ID: 31659525
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
4. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
5. AAZTA
Klasen B; Moon ES; Rösch F
Nucl Med Biol; 2021; 96-97():80-93. PubMed ID: 33839678
[TBL] [Abstract][Full Text] [Related]
6. Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach.
Lahnif H; Grus T; Pektor S; Greifenstein L; Schreckenberger M; Rösch F
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770742
[TBL] [Abstract][Full Text] [Related]
7. Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.
Pfister J; Summer D; Rangger C; Petrik M; von Guggenberg E; Minazzi P; Giovenzana GB; Aloj L; Decristoforo C
EJNMMI Res; 2015 Dec; 5(1):74. PubMed ID: 26669693
[TBL] [Abstract][Full Text] [Related]
8. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, radiolabeling, and pre-clinical evaluation of [
Ghiani S; Hawala I; Szikra D; Trencsényi G; Baranyai Z; Nagy G; Vágner A; Stefania R; Pandey S; Maiocchi A
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2351-2362. PubMed ID: 33420915
[TBL] [Abstract][Full Text] [Related]
10. Effect of the versatile bifunctional chelator AAZTA
Hofstetter M; Moon ES; D'Angelo F; Geissbühler L; Alberts I; Afshar-Oromieh A; Rösch F; Rominger A; Gourni E
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):29. PubMed ID: 33258012
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.
Weineisen M; Simecek J; Schottelius M; Schwaiger M; Wester HJ
EJNMMI Res; 2014 Dec; 4(1):63. PubMed ID: 26116124
[TBL] [Abstract][Full Text] [Related]
12.
Umbricht CA; Benešová M; Schmid RM; Türler A; Schibli R; van der Meulen NP; Müller C
EJNMMI Res; 2017 Dec; 7(1):9. PubMed ID: 28102507
[TBL] [Abstract][Full Text] [Related]
13. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
14. A comparative PET imaging study of
Ferguson S; Wuest M; Richter S; Bergman C; Dufour J; Krys D; Simone J; Jans HS; Riauka T; Wuest F
Nucl Med Biol; 2020; 90-91():74-83. PubMed ID: 33189947
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
16. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
18. [
Nock BA; Kanellopoulos P; Moon ES; Rouchota M; Loudos G; Ballal S; Yadav MP; Bal C; Mishra P; Sheokand P; Roesch F; Maina T
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986637
[TBL] [Abstract][Full Text] [Related]
19. Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β--emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate.
Müller C; Bunka M; Reber J; Fischer C; Zhernosekov K; Türler A; Schibli R
J Nucl Med; 2013 Dec; 54(12):2168-74. PubMed ID: 24198390
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA
Moon ES; Van Rymenant Y; Battan S; De Loose J; Bracke A; Van der Veken P; De Meester I; Rösch F
Molecules; 2021 Jun; 26(12):. PubMed ID: 34201111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
